# PTC299 for Treatment of Neurofibromatosis Type 2

> **NCT00911248** · PHASE2 · TERMINATED · sponsor: **PTC Therapeutics** · enrollment: 11 (actual)

## Conditions studied

- Neurofibromatosis 2

## Interventions

- **DRUG:** PTC299

## Key facts

- **NCT ID:** NCT00911248
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07-31
- **Primary completion:** 2012-03-31
- **Final completion:** 2012-03-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911248, "PTC299 for Treatment of Neurofibromatosis Type 2". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00911248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*